Commenti e discussioni su vari aspetti della ricerca sulle cellule staminali

What's in a name? Pathways in development

In this blog, Vanessa De Mello (Hippo pathway enthusiast and PhD student in the Musculoskeletal group, University of Aberdeen) explores the names behind signalling pathways that control stem cells.

During growth and development the cells that make up our body need to be precisely controlled. If a ‘stop signal’ is constantly given cells will not grow and divide. But if the lights are continually green, too many cells will grow leading to problems like cancer. It is the ‘developmental signalling pathways’ that control this and give our cells instructions on when to grow, divide, or die.

Yoshiki Sasai (1962-2014): an appreciation

Yoshiki Sasai was a visionary scientist who pioneered research at the interface between developmental biology and stem cell biology, contributing major discoveries to both fields and sowing the seeds for applications in regenerative medicine.

Stem cell banking: A UK perspective on a global challenge

The UK Stem Cell Bank was established in 2003 to store, characterise and supply ethically approved stem cells for medical research and treatment. It was the first government funded public service collection of stem cells and it has played an important role in developing and maintaining standards in the UK and internationally. So what exactly does it do and why do we need this type of stem cell banking?  Glyn Stacey, Director of the UK Stem Cell Bank, tells us more.

Non-fiction writing competition: send us your science writing, go graphical or submit a poem

Competition closed

Update 13/9/13: read the winning entries

We're running our first ever writing competition! Surprise us with your imaginative science writing, wow us with your graphic non-fiction or impress us in poetry. Upload your entry by the deadline on 30th June and you could win 300 Euros and see your work live online.

See our tips for imaginative science writing. There are also answers to common questions in our competition FAQ*

Terapie a base di cellule staminali e neuropatologie: qual è la verità?

In questo periodo, diverse dichiarazioni hanno suggerito che le cellule staminali possano già essere impiegate oggi nel trattamento di persone affette da neuropatologie. Ma cosa si sa veramente di queste terapie e come interpretare queste dichiarazioni?


Making red blood cells: A model of stem cell therapy development

Translating laboratory research into cell therapies raises many complex questions and challenges for both science and society. Social scientist Emma King spent four years following a regenerative medicine research project to examine how clinical translation might work in practice. Here, she reflects on what she learnt and what it might mean for the development of future therapies.

Commercial cell therapies in Europe – a brief introduction

Work on regenerative medicine is not only happening in academic laboratories, novel cell-based therapies are also being developed by commercial companies in Europe and across the world. Michael Morrison, a social scientist with a focus on science, technology and innovation, takes a look at what is happening in the European commercial sector.



Come fanno i pazienti ad acquisire corrette informazioni sulla ricerca? Il punto di vista di un paziente.

Federica Balzani ha 28 anni. Recentemente ha preso parte alla nostra sessione all'interno della International Public Communication of Science and Technology 2012 conference, durante la quale abbiamo discusso su quali possono essere le modalità migliori, per un paziente, di acquisire informazioni sugli ultimi risultati della ricerca scientifica. Qui, Federica condivide alcune riflessioni sul ruolo di Internet nel fornire queste informazioni, comprese le sfide poste dalla selezione e dalla affidabilità o meno di tali notizie e le sue idee su come i problemi dati da queste riflessioni possono essere affrontati.

EU funding adds value to Europe’s stem cell community

The European Commission has funded groups of European stem cell scientists to work together across national boundaries. Elena Cattaneo is coordinator of one of those groups, NeuroStemcell. Here, Elena reflects on the value of European level support for such collaborative research, and introduces the film Behind the Science - an inside view of EU research consortia.

Stem cell patents: legal aspects


*New 18 June 2012*: The EU ban on embryonic stem cell patents is legally flawed, argues a paper and public lecture by Aurora Plomer, Chair of Law and Bioethics at the University of Sheffield, UK. Find out more.

June 2011: Lately there have been several cases on the patentability of inventions related to human embryonic stem cells (hESC) in Europe. Now the first case has reached the European Court of Justice (ECJ), the highest European court, whose decision will be binding for all EU member states.

The judgement of the ECJ is still outstanding. However, the Advocate General Yves Bot offered his opinion on the case, which points towards a complete prohibition of patents for inventions relating to hESC. While the court does not have to follow the opinion, it does so in a majority of the cases.